tbuckley/cabot-search huggingface dataset:
Obituary Listing
Authors: James Allison, M Columbia, Edward Blasser, M Annandale, Donald Booker, ; Boston, Richard Burman, ; Point Clear, Clarence Cernech, ; Independence, Robert Cunningham, M Marion
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BOOK REVIEWS
Authors: J. L. SPEYER
Journal: JNCI Journal of the National Cancer Institute (1991)

Journal Article BOOK REVIEWS Get access Regional Antineoplastic Drug Delivery in the Management of Malignant Disease. Maurie Markman . Baltimore: Johns Hopkins Univ. Press , 1991 . xii, 143 pp., illus. $50. JAMES L. SPEYER JAMES L. SPEYER Division of Oncology, Ste. 4J New York University Medical Center530 First Ave. New York, NY10016 1683 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 22, 20 November 1991, Pages 1682–1683, https://doi.org/10.1093/jnci/83.22.1682-a Published: 20 November 1991
Erratum for the Research Article: “PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer” by A. Bosch, Z. Li, A. Bergamaschi, H. Ellis, E. Toska, A. Prat, J. J. Tao, D. E. Spratt, N. T. Viola-Villegas, P. Castel, G. Minuesa, N. Morse, J. Rodón, Y. Ibrahim, J. Cortes, J. Perez-Garcia, P. Galvan, J. Grueso, M. Guzman, J. A. Katzenellenbogen, M. Kharas, J. S. Lewis, M. Dickler, V. Serra, N. Rosen, S. Chandarlapaty, M. Scaltriti, J…
Journal: Science Translational Medicine (2018)
In Reply:
Authors: Murray F. Brennan
Journal: Journal of Clinical Oncology (2004)

the United States is the reason our Japanese and some European colleagues argue that chemoradiotherapy may be a good substitute for "poor" surgery.A current Intergroup trial, similar to Intergroup Trial 116, does not sufficiently consider the surgical quality issues, because surgery itself has not been a part of these two protocols.However, a proposed European trial will compare Ͼ D1 surgery with Ͼ D1 surgery plus chemoradiotherapy.This approach embraces the much-needed minimum standards for surgery and quality assurance.So, would I let a surgeon operate on me if he/she were not skilled in gastric cancer surgery?No.But what about all those patients who do?Is a surgeon who is not thinking ahead (by putting metal clips in the surgical field to guide the radiation oncologist and by placing and leaving a J-tube in until a multidisciplinary decision is made about adjuvant therapy) operating on my gastric cancer?No.For esophageal cancer surgery, we know that the mortality rates are directly related to the number of operations performed at a given institution. 13This does not even consider the quality of the surgery or the individual surgeon's skills and knowledge.It is very likely that these issues are also pertinent to gastric cancer surgery.It seems reasonable to think that the quality of surgery, skills and experience of a surgeon, morbidity, mortality, institutional infrastructure, and patient outcome are all closely related.Having read innumerable surgery/pathology notes on gastric cancer patients (and finding only a few satisfactory), I believe nearly all patients with local-regional gastric or gastroesophageal junction cancer should get a multidisciplinary evaluation first and be operated on by an experienced surgeon (preferably a surgical oncologist skilled in gastric cancer surgery).The data by Kattan et al 2 reinforce this notion.
Sellar Paraganglioma
Authors: Manjiri Karlekar, Sanjeet Kumar, Swati Jadhav, Anurag Lila, Tushar Bandgar, Nalini Shah
Journal: Clinical Nuclear Medicine (2018)

Sellar and suprasellar paragangliomas are rare. We report the case of a 19-year-old man with sellar paraganglioma with parasellar and posterior pontine extension, requiring multiple transcranial surgeries and radiotherapy. The lesion was avid on Ga DOTANOC PET-CT scan substantiating its neuroendocrine nature.
THE MISSISSIPPI VALLEY MEDICAL ASSOCIATION.
Journal: JAMA (1890)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells
Authors: M Kern
Journal: Hepatology (2002)

Recent studies have shown increased levels of cyclooxygenase-2 (COX-2) in a variety of human malignancies, including hepatocellular carcinoma (HCC), but so far it is unknown whether COX-2 contributes to the malignant growth and whether inhibition of COX-2 function modifies the malignant potential of liver tumors. COX-1 and COX-2 expression was determined in 4 liver tumor cell lines (Hep 3B, HuH-7, Hep G2, Sk-hep1) by Northern hybridization and Western immunoblot. The functional effects of the nonselective inhibitor sulindac sulfide and the COX-2 selective inhibitors SC-58635 and meloxicam were examined by 3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazoliumbromide (MTT)-assays and BrdU uptake, morphology, and TUNEL analysis of apoptosis. Apoptosis regulating proteins were analyzed by Western immunoblot. COX-1 and COX-2 expression was demonstrable in all tested liver tumor cell lines. Sulindac sulfide (50 to 400 μmol/L), SC-58635 (6,25 to 400 μmol/L), and meloxicam (6.25 to 400 μmol/L) led to a significant time- and dose-dependent reduction of cell numbers of up to 80% (P < .05). At equimolar concentrations the effect was more pronounced when COX-2 was selectively blocked. COX-2 inhibition induced apoptosis and reduced tumor cell proliferation. Apoptosis after COX-2 inhibition with SC-58635 (50 μmol/L) was independent of BCL-2, BAX, and the phosphorylation status of AKT/PKB and BAD, but correlated with activation of caspase-9, caspase-3, and caspase-6. In conclusion, selective inhibition of COX-2 leads to a marked growth inhibition of human liver tumor cells, based on the induction of apoptosis and inhibition of proliferation and, thus, may offer therapeutic and preventive potential in human hepatocarcinogenesis. (HEPATOLOGY 2002;36:885-894.)
Prepayment for Medical Care
Authors: Cecil G. Sheps, Daniel L. Drosness
Journal: New England Journal of Medicine (1961)

Utilization of ServicesThe subject of utilization of services has come more and more to the fore as health insurance has come of age. As programs of various types developed and more statistical and actuarial data became available, searching questions could be asked regarding the factors that affect the utilization of specific types of health services. With the medical-care price index advancing at twice the rate of the general consumer price index, this has become increasingly important. Thus, not only the number of insured persons but also the nature and dynamics of the use of such insured services becomes a . . .
Donor age and outcome of liver transplantation
Authors: J Hoofnagle
Journal: Hepatology (1996)

To evaluate the effect of donor age on graft and patient outcome after liver transplantation an analysis of a large-scale cohort study was performed at three tertiary referral liver transplant centers. Between April 1990 and June 1994, 772 adults underwent an initial single-organ liver transplantation. The age of the donors averaged 35 years;193 (25%) were 50 or above, the age used to define “older” donors. Groups were compared for demographic, clinical, and biochemical features. Outcome was measured using results of biochemical tests after transplantation and by graft and patient survival. Compared with younger donors, older donors were more commonly women (59% vs. 33%:P ≤ .001) and died of central nervous system causes (79% vs. 28%) as opposed to trauma (13% vs. 63%:P ≤ .001). The recipients of the two groups of donor livers did not differ in important respects. However, intraoperatively, livers from older donors were more likely to be assessed as either “poor” or “fair” as opposed to “good” (17% vs. 4%:P ≤ .001) by the harvesting surgeon and to have initial “poor” or “fair” bile production (29% vs. 18%:P ≤ .001). During the first week postoperatively, the serum aminotransferase and bilirubin levels and prothrombin times were higher in recipients of older than those of younger donor livers. During follow-up, graft survival was less for recipients of older donor livers at 3 months (81% vs.91%:P = .0001) and at 1 (76% vs. 85%:P = .007) and 2 years (71% vs. 80%:P = .005); patient survival showed similar though less marked differences. This association of donor age and poorer graft survival persisted after adjusting for many variables using bivariate and multivariate analyses. Importantly, however, the association with poor graft survival was largely among recipients of older donor livers, the quality of which was assessed as fair or poor by the harvesting surgeon; recipients of older donor livers assessed as good had a retransplant-free survival similar to that of younger donor livers (87% vs. 91% at 3 months). Thus, use of older donor livers, the quality of which are judged to be good by the harvesting surgeon, is not associated with a decrease in patient or graft survival after liver transplantation. differences. This association of donor age and poorer graft survival persisted after adjusting for many variables using bivariate and multivariate analyses. Importantly, however, the association with poorer graft survival was largely among recipients of older donor livers, the quality of which was assessed as fair or poor by the harvesting surgeon; recipients of older donor livers, the quality of which was assessed as fair or poor by the harvesting surgeon; recipients of older donor livers assessed as good had a retransplant-free survival similar to that of younger donor livers (87% vs. 91% at 3 months). Thus, use of older donor livers, the quality of which are judged to be good by the harvesting surgeon, is not associated with a decrease in patient or graft survival after liver transplantation.
Varicella-Related Deaths Among Adults— United States, 1997
Journal: JAMA (1997)

During January-April 1997, state health departments reported three fatal cases of varicella (chickenpox) to CDC. All three cases occurred in young adult women who were unvaccinated and susceptible to varicella and who were infected by exposure to unvaccinated preschool-aged children with typical cases of varicella. This report summarizes these three cases, which indicate that preventable varicella-related deaths continue to occur in the United States. In addition, the report re-emphasizes the recommended strategies for preventing varicella.
Recipe for hearing loss: noise, hypertension and fatty diet
Authors: C. A. Raymond
Journal: JAMA (1986)

"NOISE IS the most impertinent of all forms of interruption. It is not only an interruption, but also a disruption of thought," said 19th-century German philosopher Arthur Schopenhauer. As more Americans live—and work— longer, the collective burden of urban din, hypertension, and high cholesterol diets may disrupt not only their ability to hear themselves think, but also to hear the world around them, according to recent research by Harold C. Pillsbury, MD. Hearing loss may appear to be an inevitable part of aging, but studies of hearing among tribes living in quiet, remote areas of the Sudan show that presbycusis (high-frequency nerve hearing loss in the aged) is not inevitable (<i>Trans AAOO</i>1964;68:433-444). And while there is an extensive body of literature demonstrating the effects of noise on hearing loss, the intrusion of noise alone may not completely explain the degree of hearing loss among industrial populations, according to Pillsbury,
Blood flow and portal hypertension
Journal: Hepatology (1995)

Background/Aim: Brain edema is a common fatal complication in acute liver failure. It is related to an acute change in brain osmolarity secondary to the glial accumulation of glutamine. Since high cerebral blood flow (CBF) precedes cerebral herniation in fulminant hepatic failure we first determined if an increase in brain water and glutamine are prerequisite to a rise in CBF in a model of ammonia-induced brain edema. Secondly, we determined if such a cerebral hyperperfusion is mediated by nitric oxide synthase (NOS).Methods: Male rats received an end-to-side portacaval anastomosis (PCA). At 24 h, they were anesthetized with ketamine and infused with ammonium acetate (55 μM/kg per min). Studies were performed at 60, 90, 120, 150 and 180 min after starting the ammonia infusion and once the intracranial pressure had risen three-fold (mean 210′). Brain water (BW) was measured using the gravimetry method and CBF with the radioactive microsphere technique. Glutamine (GLN) in the CSF was sampled via a cisterna magna catheter. The neuronal NOS was specifically inhibited by 1-2-trifluoromethylphenyl imidazole (TRIM, 50 mg/kg intraperitoneally) and in separate studies nonspecifically by N-omega-nitro-l-arginine (l-NNA, 2 μg/kg per min intravenously)Results: At 90′, brain water was significantly increased (P<0.015) as compared to the 60′ group while CBF was significantly different at 150′. A significant correlation was observed between values of CBF and brain water (r=0.88, n=36, P<0.001). Administration of either TRIM or l-NNA did not prevent the development of cerebral hyperperfusion and edema.Conclusion: We observed that cerebral hyperemia follows an initial rise in brain water content, rather than in the cerebrospinal fluid concentration of glutamine. The rise in CBF further correlated with brain water accumulation and was of critical importance for the development of intracranial hypertension. The unique mechanism for the rise in CBF in hyperammonemia was not prevented by NOS inhibition indicating that NO is not the mediator of high CBF and intracranial hypertension.
Neurology
Authors: R. J. Joynt
Journal: JAMA (1990)

A major theme in neurology for the last several years has been clinical trials of therapy for disorders that were thought to be untreatable. The course of Parkinson's disease, for example, has been greatly modified by the introduction of therapies that increase activity in the dopaminergic system. During this last year, another approach to this disease has been undertaken through attempts to delay and slow its manifestations. The variable course and heterogeneous manifestations of Parkinson's disease make clinical trials difficult. However, a multicenter controlled clinical trial with many safeguards was devised.<sup>1</sup>The clinical trial is still in progress, but the interim results show that 10 mg/d of selegiline (Deprenyl), a monoamine oxidase inhibitor, slowed the end point, which was a decision to treat the patient with levodopa therapy. The treatment also had a significant effect in slowing the time until it was necessary for the patient to give up
Postexposure rabies prophylaxis with human rabies immune globulin
Authors: M. A. Hattwick
Journal: JAMA (1974)

Human rabies immune globulin (HRIG) was given in doses of 10,15, and 40 international units (IU)/kg of body weight to groups of volunteers. It was administered alone and in combination with 16 or 23 injections of duck embryo rabies vaccine (DEV). Administration of HRIG resulted in the early appearance of antibody but inhibited the development of active antibody in all groups receiving DEV. Forty-six percent of persons receiving HRIG at 40 IU/kg and 16 doses of DEV had serum rabies-neutralizing antibody titers of less than 1:5 at 70 days. This immunosuppression was overcome in the groups receiving 23 doses of DEV. Based on these data, post-exposure rabies prophylaxis series should consist of HRIG between 15 and 40 IU/kg plus a 23-dose course of DEV.
A method for understanding three-dimensional coronary anatomy
Authors: T. A. Sos
Journal: JAMA (1980)

A simple method for interpreting and reviewing the anatomy of the coronary arteries as seen on angiograms uses the concept of two imaginary circles around the interventricular and atrioventricular grooves, respectively. The hands and fingers of the viewer are used to represent the various cardiac structures so that the anatomic location of vessels in various angiographic projections may be properly understood. (<i>JAMA</i>243:252-254, 1980)
False-Negative Qualitative Cardiac Troponin T in a 79-Year-Old Man With Myocardial Infarction
Authors: Michael E. Ottlinger
Journal: JAMA (1997)

<h3>To the Editor.</h3> —Cardiac troponin T (cTnT) thought to be a more specific indicator of myocardial cell necrosis than serum creatine kinase—MB (CK-MB).<sup>1-3</sup>The CardiacT assay is the Food and Drug Administration—approved point-of-care device increasingly used in the detection of cTnT. To our knowledge, this is the first report of a case in which the CardiacT assay failed to detect myocardial infarction (MI) in contradiction to other biochemical markers. A 79-year-old man, with a history of non-Q wave MI and chronic stable angina diagnosed 7 years earlier, presented to the emergency department with complaints of chest pain while walking. Cardiac examination showed a normal S<sub>1</sub>, S<sub>2</sub>, no S<sub>3</sub>, and a grade 2/4 harsh systolic murmur that was heard best at the right upper sternal border. A 12-lead electrocardiogram (ECG) demonstrated a sinus rhythm with a rate of 92 and right bundle branch block. Laboratory data are
Mixing Metaphors
Authors: Benjamin W. Corn, Eli Sharon
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
A World Panorama of Health Education Seen Through Meetings of the Health Section of the World Federation of Education Associations, Geneva, Switzerland, July 27-August 2, 1929.
Journal: JAMA (1931)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Drop-in
Authors: John L. McClenahan
Journal: Annals of Internal Medicine (2002)

On Being a Patient20 August 2002Drop-inJohn L. McClenahan, MDJohn L. McClenahan, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-137-4-200208200-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Early on Monday morning, when I had an overloaded schedule before me, Angela, my receptionist, buzzed me on the intercom.“A full house, doctor,” she murmured. “And Doctor B. just walked in. He wants to see you.”“Refresh my memory.”“It goes back to Cleve—”“Lord help us! Appointment?”“Surely you jest.”“I'll be right out.”So, I said to myself, he finally made it. Five appointments in 3 months. He never showed up for four of them and reeled in for the fifth so contrite and incoherent that I begged him to forget the whole thing and go home. ... Author, Article, and Disclosure InformationAuthors: John L. McClenahan, MDCorresponding Author: John L. McClenahan, MD, 4703 Pocahontas Avenue, Richmond, VA 23226. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byLife on the Receiving End: A Qualitative Analysis of Health Providers??? Illness Narratives 20 August 2002Volume 137, Issue 4 Page: 293-294 Keywords Bladder Breathing Coffee Memory Milk Mouth Pelvis Sarcoma Technicians Ureter ePublished: 20 August 2002 Issue Published: 20 August 2002 Copyright & PermissionsCopyright © 2002 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...